Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups.
Ahmed A, Koza E, Shi V, Ma M, Haq M, Kottner J, Garg A, Ingram JR, Ezzedine K, Spuls PI, Beeckman D, Wolkenstein P, Fransen F, Noe MH, Langbroek GB, Bauer A, Thorlacius L, Horbach SER, Layton A, Apfelbacher C, Cahn BA, Pearlman R, Schlessinger DI, Alam M. Ahmed A, et al. Among authors: ingram jr. Arch Dermatol Res. 2024 Mar 18;316(4):109. doi: 10.1007/s00403-023-02812-1. Arch Dermatol Res. 2024. PMID: 38498269 No abstract available.
Feasibility of daily pain measurement using text messages in hidradenitis suppurativa clinical trials; data from the THESEUS study.
Hasan SB, Bates J, Cannings-John R, Collier F, Evans J, Gibbons A, Harris C, Howells L, Hood K, Howes R, Leighton P, Riaz M, Rodrigues J, Stanton H, Thomas KS, Thomas-Jones E, Ingram JR. Hasan SB, et al. Among authors: ingram jr. Br J Dermatol. 2024 Apr 17;190(5):775-777. doi: 10.1093/bjd/ljae057. Br J Dermatol. 2024. PMID: 38365908 No abstract available.
The Global Hidradenitis Suppurativa Atlas (GHiSA) Methodology: Combining Global Proportions in a Pooled Analysis.
Bouazzi D, Andersen RK, Vinding GR, Medianfar CE, Nielsen SM, Saunte DML, Chandran NS, van der Zee HH, Zouboulis CC, Benhadou F, Villumsen B, Alavi A, Ibekwe PU, Hamzavi IH, Ingram JR, Naik HB, Garg A, Boer J, Christensen R, Jemec GBE. Bouazzi D, et al. Among authors: ingram jr. Dermatology. 2024 Feb 14. doi: 10.1159/000536389. Online ahead of print. Dermatology. 2024. PMID: 38354718
Protocol of a scoping review of outcome domains in dermatology.
Nadir U, Ahmed A, Yi MD, Hisham FI, Dave L, Kottner J, Ezzedine K, Garg A, Ingram JR, Jemec GBE, Spuls PI, Kirkham JJ, Cahn B, Alam M. Nadir U, et al. Among authors: ingram jr. BMJ Open. 2024 Feb 6;14(2):e079632. doi: 10.1136/bmjopen-2023-079632. BMJ Open. 2024. PMID: 38320843 Free PMC article.
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study.
Ring HC, Thorsen J, Kirby B, Ingram JR, Rosenø NAL, Holgersen N, Nielsen VW, Thein Aagaard DN, Maul JT, Wu JJ, Thyssen JP, Egeberg A, Thomsen SF. Ring HC, et al. Among authors: ingram jr. Br J Dermatol. 2024 Apr 17;190(5):769-771. doi: 10.1093/bjd/ljae042. Br J Dermatol. 2024. PMID: 38305415 No abstract available.
Clinical relevance and uptake of core outcome sets in dermatology.
Ahmed A, Koza E, Shi V, Ma M, Haq M, Kottner J, Garg A, Ingram JR, Ezzedine K, Spuls PI, Beeckman D, Wolkenstein P, Fransen F, Noe MH, Langbroek GB, Bauer A, Thorlacius L, Horbach SER, Layton A, Apfelbacher C, Cahn BA, Pearlman R, Schlessinger DI, Alam M. Ahmed A, et al. Among authors: ingram jr. Arch Dermatol Res. 2024 Jan 20;316(2):78. doi: 10.1007/s00403-023-02814-z. Arch Dermatol Res. 2024. PMID: 38244063 No abstract available.
421 results